Simpson Thacher represented the underwriters, led by Morgan Stanley & Co. LLC, J.P. Morgan Securities LLC and Goldman Sachs & Co. LLC, in connection with the initial public offering by Bioventus Inc. (“Bioventus”) of 9,200,000 shares of its Class A common stock, inclusive of the underwriters’ full exercise of their option to purchase additional shares, which raised approximately $120 million in gross proceeds. The initial public offering closed on February 16, 2021.
Bioventus is a global medical device company focused on developing and commercializing clinically differentiated, cost efficient and minimally invasive treatments that engage and enhance the body’s natural healing process. Bioventus’s portfolio of products is grouped into three verticals based on customer focus: osteoarthritic joint pain treatment and joint preservation, spinal bone graft substitutes and minimally invasive fracture treatment.
The Simpson Thacher team for this transaction included Art Robinson, Hui Lin, Ben Heriaud, Niyati Roy and Gianna Ceophas (Capital Markets); Vanessa Burrows (Healthcare Regulatory); Sophie Staples and Abigail Hopper (Tax); Larry Moss and Eric Wolf (Executive Compensation and Employee Benefits); Shari Ness (Public Company Advisory Practice); Genevieve Dorment (IP); and Jennie Getsin (FINRA & Blue Sky).